Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Proteinase-activated receptor 2 (PAR(2)) in cholangiocarcinoma (CCA) cells: effects on signaling and cellular level.

Kaufmann R, Hascher A, Mussbach F, Henklein P, Katenkamp K, Westermann M, Settmacher U.

Histochem Cell Biol. 2012 Dec;138(6):913-24. doi: 10.1007/s00418-012-1006-4. Epub 2012 Aug 15.

PMID:
22892662
2.

Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2-mediated hepatocellular carcinoma cell invasion.

Kaufmann R, Oettel C, Horn A, Halbhuber KJ, Eitner A, Krieg R, Katenkamp K, Henklein P, Westermann M, Böhmer FD, Ramachandran R, Saifeddine M, Hollenberg MD, Settmacher U.

Carcinogenesis. 2009 Sep;30(9):1487-96. doi: 10.1093/carcin/bgp153. Epub 2009 Jun 22.

3.

Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4.

Kaufmann R, Rahn S, Pollrich K, Hertel J, Dittmar Y, Hommann M, Henklein P, Biskup C, Westermann M, Hollenberg MD, Settmacher U.

J Cell Physiol. 2007 Jun;211(3):699-707.

PMID:
17323377
4.

Proteinase-activated receptor-2 activating peptides: distinct canine coronary artery receptor systems.

Saifeddine M, Seymour ML, Xiao YP, Compton SJ, Houle S, Ramachandran R, MacNaughton WK, Simonet S, Vayssettes-Courchay C, Verbeuren TJ, Hollenberg MD.

Am J Physiol Heart Circ Physiol. 2007 Dec;293(6):H3279-89. Epub 2007 Aug 31.

5.

Epidermal growth factor receptor transactivation is required for proteinase-activated receptor-2-induced COX-2 expression in intestinal epithelial cells.

Hirota CL, Moreau F, Iablokov V, Dicay M, Renaux B, Hollenberg MD, MacNaughton WK.

Am J Physiol Gastrointest Liver Physiol. 2012 Jul;303(1):G111-9. doi: 10.1152/ajpgi.00358.2011. Epub 2012 Apr 19.

6.

2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist.

McGuire JJ, Saifeddine M, Triggle CR, Sun K, Hollenberg MD.

J Pharmacol Exp Ther. 2004 Jun;309(3):1124-31. Epub 2004 Feb 19.

7.

Dual effect of the novel peptide antagonist K-14585 on proteinase-activated receptor-2-mediated signalling.

Goh FG, Ng PY, Nilsson M, Kanke T, Plevin R.

Br J Pharmacol. 2009 Dec;158(7):1695-704. doi: 10.1111/j.1476-5381.2009.00415.x. Epub .

9.

Proteinase-activated receptor-2 mediated inhibition of TNFalpha-stimulated JNK activation - A novel paradigm for G(q/11) linked GPCRs.

McIntosh K, Cunningham MR, Cadalbert L, Lockhart J, Boyd G, Ferrell WR, Plevin R.

Cell Signal. 2010 Feb;22(2):265-73. doi: 10.1016/j.cellsig.2009.09.028. Epub 2009 Sep 23.

10.

PAR-2 activation regulates IL-8 and GRO-alpha synthesis by NF-kappaB, but not RANTES, IL-6, eotaxin or TARC expression in nasal epithelium.

Rudack C, Steinhoff M, Mooren F, Buddenkotte J, Becker K, von Eiff C, Sachse F.

Clin Exp Allergy. 2007 Jul;37(7):1009-22.

PMID:
17581194
11.

EGF receptor transactivation and MAP kinase mediate proteinase-activated receptor-2-induced chloride secretion in intestinal epithelial cells.

van der Merwe JQ, Hollenberg MD, MacNaughton WK.

Am J Physiol Gastrointest Liver Physiol. 2008 Feb;294(2):G441-51. Epub 2007 Nov 21.

12.

Proteinase-activated receptor-2-mediated relaxation in mouse tracheal and bronchial smooth muscle: signal transduction mechanisms and distinct agonist sensitivity.

Kawabata A, Kubo S, Ishiki T, Kawao N, Sekiguchi F, Kuroda R, Hollenberg MD, Kanke T, Saito N.

J Pharmacol Exp Ther. 2004 Oct;311(1):402-10. Epub 2004 Jun 15.

13.
14.

Neutrophil elastase acts as a biased agonist for proteinase-activated receptor-2 (PAR2).

Ramachandran R, Mihara K, Chung H, Renaux B, Lau CS, Muruve DA, DeFea KA, Bouvier M, Hollenberg MD.

J Biol Chem. 2011 Jul 15;286(28):24638-48. doi: 10.1074/jbc.M110.201988. Epub 2011 May 16.

15.

Tumor-derived trypsin enhances proliferation of intrahepatic cholangiocarcinoma cells by activating protease-activated receptor-2.

Nakanuma S, Tajima H, Okamoto K, Hayashi H, Nakagawara H, Onishi I, Takamura H, Kitagawa H, Fushida S, Tani T, Fujimura T, Kayahara M, Ohta T, Wakayama T, Iseki S, Harada S.

Int J Oncol. 2010 Apr;36(4):793-800.

PMID:
20198321
16.

The protease-activated receptor-2-specific agonists 2-aminothiazol-4-yl-LIGRL-NH2 and 6-aminonicotinyl-LIGRL-NH2 stimulate multiple signaling pathways to induce physiological responses in vitro and in vivo.

Flynn AN, Tillu DV, Asiedu MN, Hoffman J, Vagner J, Price TJ, Boitano S.

J Biol Chem. 2011 May 27;286(21):19076-88. doi: 10.1074/jbc.M110.185264. Epub 2011 Apr 5.

17.

Statins prevent tissue factor induction by protease-activated receptors 1 and 2 in human umbilical vein endothelial cells in vitro.

Banfi C, Brioschi M, Lento S, Pirillo A, Galli S, Cosentino S, Tremoli E, Mussoni L.

J Thromb Haemost. 2011 Aug;9(8):1608-19. doi: 10.1111/j.1538-7836.2011.04366.x.

18.

A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.

Hov H, Holt RU, Rø TB, Fagerli UM, Hjorth-Hansen H, Baykov V, Christensen JG, Waage A, Sundan A, Børset M.

Clin Cancer Res. 2004 Oct 1;10(19):6686-94.

19.

Modified proteinase-activated receptor-1 and -2 derived peptides inhibit proteinase-activated receptor-2 activation by trypsin.

Al-Ani B, Saifeddine M, Wijesuriya SJ, Hollenberg MD.

J Pharmacol Exp Ther. 2002 Feb;300(2):702-8.

20.

Effects of trypsin, thrombin and proteinase-activated receptors on guinea pig common bile duct motility.

Huang SC.

Regul Pept. 2012 Nov 10;179(1-3):1-5. doi: 10.1016/j.regpep.2012.08.011. Epub 2012 Sep 4.

PMID:
22960409
Items per page

Supplemental Content

Write to the Help Desk